Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180‐034 (NCT00123474) study. Here we present the final 7‐year analysis of this pivotal study, the longest follow‐up to da...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Hematol
Prif Awduron: Shah, Neil P., Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E., Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, Saglio, Giuseppe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2016
Pynciau:
Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094534/
https://ncbi.nlm.nih.gov/pubmed/27192969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24423
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg